✨ Onyx Summary Belite Bio priced an underwritten public offering of 2,272,727 ADSs at $154.00 per ADS, with a 30-day option for underwriters to purchase up to an additional 340,909 ADSs, for expected gross proceeds of about $350 million before fees and expenses, with closing anticipated around
✨ Onyx Summary Belite Bio commenced an underwritten public offering of ADSs, with all shares sold by the company and an additional 30-day underwriter option for extra ADSs, subject to market conditions. Proceeds are earmarked for commercialization buildout, pipeline development and expansion, and general corporate purposes, with Morgan Stanley, Leerink, BofA
✨ Onyx Summary Belite Bio reported positive topline Phase 3 DRAGON results showing its oral therapy tinlarebant met the primary endpoint in Stargardt disease type 1, delivering a statistically significant 35.7% reduction in retinal lesion growth versus placebo over 24 months in 104 adolescent patients. The company said the safety
✨ Onyx Summary Recursion announced it will host a December 8, 2025 company webinar to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial evaluating REC-4881 monotherapy in patients with familial adenomatous polyposis, including new safety and efficacy data. Salt Lake City, Dec. 01, 2025 – Recursion (Nasdaq:
✨ Onyx Summary Cellares appointed Ali Soleymannezhad as Chief Commercial Officer to lead global commercial strategy as it scales its IDMO Smart Factory network across the U.S., Europe, and Japan, positioning the company for commercial expansion ahead of a potential IPO. The hire underscores Cellares’ strategy to address global cell
✨ Onyx Summary Seer, Inc. announced publication in Nature Genetics of a large-scale GWAS demonstrating that its Proteograph platform’s peptide-level mass spectrometry is critical for accurately validating protein–gene associations and reducing false signals common in affinity-based proteomics. The study, spanning ~1,600 multi-ethnic samples, shows that up to one-third
✨ Onyx Summary Legend Biotech Corporation was named Foreign Investor of the Year at the 2025 Flanders International Business Awards, recognizing its long-term investment and expansion of CAR-T cell therapy manufacturing in Ghent, Belgium. The award reflects a €165 million joint investment with Johnson & Johnson that has scaled Ghent into
✨ Onyx Summary Rocket Pharmaceuticals announced that CEO Dr. Gaurav Shah will participate in a fireside chat and investor meetings at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance provides a platform to engage investors on Rocket’s late-stage gene therapy pipeline and strategic priorities as it
✨ Onyx Summary Lexicon Pharmaceuticals announced that company management will participate in fireside chats at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025, with live and replay access available through the company’s investor website. THE WOODLANDS,
✨ Onyx Summary enGene Holdings Inc. announced that Chief Strategy and Operations Officer Alex Nichols, Ph.D., will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a webcast available via the company’s investor website. BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene”
✨ Onyx Summary Foghorn Therapeutics announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025, with a webcast available via the company’s investor website. CAMBRIDGE, Mass., Nov. 25, 2025 – Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a
✨ Onyx Summary Belite Bio assigned its rights and obligations under its exclusive Columbia University license from its Hong Kong subsidiary to its Swiss subsidiary as part of a capital contribution. The move positions the company for potential future sublicensing or collaborations while leaving current operations unchanged. SAN DIEGO, November 24,
✨ Onyx Summary Ocugen announced that CEO and co-founder Dr. Shankar Musunuri will present at NobleCon21 on December 3, 2025, where he plans to outline progress toward the company’s goal of “three BLAs in three years” and discuss 2026 catalysts across its modifier gene therapy platform for blindness diseases. The
✨ Onyx Summary Keros Therapeutics, Inc. announced the final results of its cash tender offer, repurchasing 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender, which applied a final proration factor of roughly 62.3%, concludes
✨ Onyx Summary Perspective Therapeutics announced that members of its senior leadership team will participate in fireside chats and investor meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. SEATTLE, Nov. 20, 2025 – November 20, 2025
✨ Onyx Summary Avidity Biosciences launched an FDA-authorized Managed Access Program in the United States to provide investigational delpacibart zotadirsen to eligible patients with Duchenne muscular dystrophy amenable to exon 44 skipping, addressing a population with no approved exon-skipping therapies. The program aligns with Avidity’s planned 2026 BLA submission for
